CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma

Background: Chemoradiotherapy (CRT) is currently performed for patients with advanced esophageal carcinoma. Sensitivity of tumours to CRT differs from one case to another and may be influenced by the expression of biological molecules. The aim of this study was to identify biological markers which could predict sensitivities of esophageal squamous cell carcinoma (ESCC) to CRT.

Methods: A total of 84 patients with stage I–IV ESCC were evaluated. The cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) and carcinoembryonic antigen (CEA) levels were measured before CRT by enzyme-linked immunosorbent assays in patients with primary ESCCs using 3.4?ng ml^?1 and 3.3?ng ml^?1, respectively, as cut-off values. The relationships between pretreatment expression of CYFRA 21-1 and CEA and the effectiveness of CRT were analysed.

Results: The complete response (CR) rates of the primary tumours estimated by computed tomography in patients with high levels of CYFRA21-1 and CEA were 10% (3/30) and 4.2% (1/24), while in cases with low CYFRA21-1 and CEA the CR rates were 50% (27/54) and 48.3% (29/60), respectively (p?=?0.002 and 0.003). The effective rates (CR+PR) in CYFRA21-1 high and low groups were 60% (18/30) and 96.3% (52/54), while in CEA high and low groups they were 58.3% (14/24) and 93.3% (56/60), respectively (p?=?0.013 and 0.013).

Conclusion: CYFRA21-1 and CEA may be helpful in predicting the responsiveness in ESCC of primary lesions to CRT, although the results should be confirmed in larger, more homogeneous studies.     

Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus

To determine the clinical efficacy of serum concentration of cytokeratin 19 fragment (CYFRA 21-1), sera from 66 patients with oesophageal squamous cell carcinoma were examined, and 54 surgically resected specimens were immunohistochemically stained for cytokeratin 19 (CK-19). The patients with positive CK-19 staining in the tissues of their carcinomas had significantly higher serum CYFRA 21-1 levels compared with those with negative CK-19 staining. When the cut-off value was defined as 2.0 ng/mL, CYFRA 21-1 had a higher positive ratio than that of either squamous cell carcinoma antigen (SCC-Ag) or carcinoembryonic antigen (CEA). Serum CYFRA 21-1 level increased significantly along with the clinical stages. In addition, serum CYFRA 21-1 level served as a prognostic factor for patients with oesophageal carcinoma after surgery, whilst SSC-Ag and CEA is not connected with the outcome. These findings suggest that the serum CYFRA 21-1 probably originated from the tumour tissue is an important marker for determining the stage and outcome of oesophageal carcinoma.     

血清CEA、NSE、CYFRA21-1 联合支气管活检在周围型肺癌诊断鉴别中的应用

目的:探讨血清肿瘤标志物癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA21-1)联合经纤维支气管镜肺活检(TBLB)在周围型肺癌诊断鉴别中的应用价值。方法:选择2012年9月到2014年9月在我院临床确诊的402例周围型肺癌患者。检测所有患者的血清CEA、NSE和CYFRA21-1的浓度及分析TBLB检测结果,分析不同病理类型和不同病灶直径大小时各项检测指标及联合检测的阳性检出率。结果:所有肺癌患者中,血清CEA、NSE、CYFRA21-1和TBLB的阳性检出率分别为51.74%,35.07%,41.79%和60.70%。四项指标联合检测的阳性检出率为89.05%,明显分别高于四项指标的阳性检出率(均P0.05)。腺癌、鳞癌、小细胞肺癌及其他类型肺癌组四项联合检测的阳性检出率明显高于四项单独检测(均P0.05)。病灶直径为2 cm、2-6 cm和6 cm时,四项联合检测的阳性检出率明显高于四项单独检测(均P0.05)。结论:血清CEA、NSE、CYFRA21-1联合TBLB检测周围型肺癌较单项检测,阳性检出率高,值得在临床上推广应用。     

鼻咽癌患者血清中CYFRA21-1 和SCCAg水平检测的临床意义

目的:探讨血清中CYFRA21-1和SCCAg水平对鼻咽癌患者临床病理特征及恶性程度的评价作用。方法:选择2009年4月-2010年12月期间在我院确诊为鼻咽癌并接受放疗的55例患者作为研究的实验组,同期体检的60例健康志愿者作为研究的对照组,检测血清中CYFRA21-1和SCCAg水平以及肿瘤组织中Livin、CDK6、Caspase-3、Caspase-9的m RNA含量。结果:实验组患者血清中CYFRA21-1和SCCAg的水平显著高于对照组(P0.05);TNM分期越高、分化程度越低,血清中CYFRA21-1、SCCAg含量以及肿瘤组织中Livin、CDK6的m RNA含量越高,肿瘤组织中Caspase-3、Caspase-9的m RNA含量越低(P0.05);CYFRA21-1含量与肿瘤组织中Livin、CDK6的m RNA含量呈正相关,与Caspase-3、Caspase-9的m RNA含量呈负相关,相关系数r分别为0.723、0.693、-0.714、-0.648;SCCAg含量与肿瘤组织中Livin、CDK6的m RNA含量呈正相关,与Caspase-3、Caspase-9的m RNA含量呈负相关,相关系数r分别为0.645、0.703、-0.751、-0.681。结论:血清中CYFRA21-1和SCCAg水平能够反应鼻咽癌患者的肿瘤分期、分化程度以及肿瘤组织中细胞的增殖活力,是用于评价鼻咽癌患者临床病理特征及恶性程度的理想指标。     

血清及胸腔积液中CA19-9、SCC-Ag及CYFRA21-1对肺癌诊断意义的对比研究

目的:探讨肺癌患者血清及胸腔积液中的糖蛋白抗原19-9(CA19-9)、鳞状细胞癌抗原(SCC-Ag)和细胞角蛋白19片段(CYFRA21-1)对肺癌的诊断意义。方法:选取2016年1月到2017年6月在我院接受治疗的肺癌患者67例作为肺癌组,另选取我院同期收治的肺良性病变患者55例纳入良性病变组。采用电化学发光法检测并对比两组患者血清及胸腔积液中的CA19-9、SCC-Ag和CYFRA21-1水平,比较所有研究对象血清及胸腔积液中CA19-9、SCC-Ag和CYFRA21-1的阳性率并分析其诊断价值。结果:肺癌组患者血清及胸腔积液中的CA19-9、SCC-Ag和CYFRA21-1水平显著高于良性病变组,有统计学差异(P0.05)。CA19-9、SCC-Ag和CYFRA21-1在胸腔积液中的阳性率高于在血清中的阳性率,有统计学差异(P0.05)。胸腔积液中CA19-9、SCC-Ag和CYFRA21-1单项检测对肺癌的灵敏度显著高于血清检测,血清及胸腔积液中CA19-9、SCC-Ag和CYFRA21-1三项联合检测的灵敏度、特异性、阳性预测值均高于单项检测,差异均有统计学意义(P0.05)。结论:肺癌患者血清及胸腔积液中CA19-9、SCC-Ag和CYFRA21-1呈现高表达,三项指标联合检测可提高诊断肺癌的灵敏度、特异性和阳性预测值。     

Serum CYFRA21-1 as a prognostic marker for patients with undifferentiated nasopharyngeal carcinoma

The purpose of this study was to evaluate the potential of serum CYFRA21-1 and carcinoembryonic antigen (CEA) as prognostic markers in patients with undifferentiated nasopharyngeal carcinoma. Sixty-one patients who received definitive radiotherapy/chemoradiotherapy were analysed retrospectively. We investigated the association of the follow-up results with pretreatment level, post-treatment level and change of serum CYFRA21-1 and CEA, respectively. Patients with low pretreatment CYFRA21-1 had a significantly better overall survival. There were no significant associations among the remaining serum markers, and the survival and recurrence rates on multivariate analysis. The present study shows that pretreatment CYFRA21-1 level is a potential factor for predicting long-term survival.     

血清CEA、CA19-9、CYFRA21-1与结直肠腺癌的相关性分析

目的:探究血清癌胚抗原(carcinoembryonic antigen,CEA)、糖类抗原19-9、细胞角蛋白19片段(cytokeratin19 fragements,CYFRA21-1)与结直肠腺癌的病理相关性.方法:选择于我院接受治疗的80例结直肠腺癌患者为病例组,选择同期于我院接受治疗的50例良性结直肠病变患...     

肺癌患者血清CEA、CYFRA21-1和NSE的检测及临床意义

目的探讨外周血癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)和神经元特异性烯醇化酶(NSE)的检测对肺癌的诊断、病理分型和疗效判断的临床用价值。方法采用化学发光法检测了62例肺癌患者、54例良性肺部疾病患者、36例健康人、40例肺癌患者手术前后血清CEA、CYFRA21-1和NSE的水平。结果肺癌患者手术前血清CEA、CYFRA21-1和NSE的含量明显高于良性肺部疾病组及正常对照组(P0.01)。鳞癌组、腺癌组和小细胞癌组之间肿瘤标志物CEA、CYFRA21-1和NSE水平差异有统计学意义。CEA阳性率以腺癌组最高(84%),CYFRA21-1阳性率以鳞癌组最高(85.2%),NSE阳性率以小细胞癌组最高(80.0%)。手术治疗后未复发转移组CEA、CYFRA21-1和NSE水平低于术前,而复发转移组与术前比变化不显著(P0.05)。结论血清CEA、CYFRA21-1和NSE的检测对不同病理类型肺癌患者的诊断、病情检测及疗效判断有较好的临床参考价值。     

NSE、CEA 和CYFRA21-1 测定对胸腔积液的诊断价值

目的:探讨神经元烯醇化酶(NSE)、癌胚抗原(CEA)和细胞角蛋白19(CYFRA21-1)测定对胸腔积液的诊断价值。方法:选择我院2009年4月～2011年9月收治的胸腔积液患者89例作为研究对象,按照胸腔积液性质分为两组,良性组47例,恶性组42例,对两组的NSE、CEA和CYFRA21-1测定结果进行比较分析。结果:恶性组患者血清和胸腔积液中NSE、CEA和CYFRA21-1水平均明显高于良性组,组间差异有统计学意义(P<0.05);NSE、CEA和CYFRA21-1联合检测对恶性胸腔积液的敏感性均明显高于单独NSE、CEA和CYFRA21-1检测,差异有统计学意义(P<0.05)。结论:NSE、CEA和CYFRA21-1测定对胸腔积液具有临床诊断价值,且三者联合检测能够明显提高诊断敏感性。     

血清细胞角蛋白19、神经元特异性烯醇化酶及鳞状上皮细胞癌抗原在小细胞肺癌诊断及病情评估中的作用研究

摘要 目的：分析血清细胞角蛋白19（CK19）、神经元特异性烯醇化酶（NSE）及鳞状上皮细胞癌抗原（SCCA）在小细胞肺癌诊断及病情评估中的作用。方法：选择我院自2020年1月至2022年7月收治的85例小细胞肺癌患者作为观察组,另选同期的85例肺部良性疾病患者作为对照组。检测两组血清CK19、NSE、SCCA表达水平,比较两组血清CK19、NSE、SCCA表达水平及其阳性率,使用ROC曲线下面积（AUC）分析上述指标对小细胞肺癌的诊断效能,观察小细胞肺癌不同分期患者血清CK19、NSE、SCCA表达水平的差异性,分析观察组治疗前后血清CK19、NSE、SCCA表达水平的变化情况。结果：观察组血清CK19、NSE、SCCA表达水平均较对照组高（P＜0.05）;观察组血清CK19、NSE和SCCA的阳性率均较对照组高（P＜0.05）;经ROC曲线分析,血清CK19、NSE联合SCCA诊断小细胞肺癌的敏感度为91.23 %,特异度为84.67 %,AUC为0.910;在85例小细胞肺癌患者中,临床分期为局限期33例、广泛期52例;广泛期患者血清CK19、NSE、SCCA表达水平均高于局限期患者（P＜0.05）。结论：血清CK19、NSE联合SCCA诊断小细胞肺癌的效能较好,三者均与患者病情严重程度有关,有利于此病的早期诊断和病情评估,值得进一步研究应用。     

CEA和CYFRA21-1在原发性肺癌诊断中的应用价值分析

目的:评价血清癌胚抗原(carcinoembryonic antigen,CEA)和细胞角蛋白19的片段(CYFRA21-1)水平对原发性肺癌的诊断价值。方法:回顾性分析2012年5月~2013年5月我科收治的329例肺癌患者和192例肺部良性病变患者的临床资料。结果:肺癌患者血清CEA或CYFRA21-1水平随着肺癌的分期呈现逐渐上升的趋势(P0.001,P0.01)。以血清CEA≥3.4μg/L作为诊断条件诊断肺癌的灵敏度、特异度和阳性预计值预计值分别为67%、62%和75.2%;以血清CYFRA-21≥5.0 ug/L作为诊断条件诊断原发性肺癌的灵敏度、特异度和阳性预计值预计值分别为48%、87%和86.3%;以血清CEA≥3.4 ug/L和CYFRA-21≥5.0 ug/L共同作为诊断条件推断原发性肺癌的灵敏度、特异度和阳性预计值预计值分别为48%、87%和86.3%;良性肺部疾病患者中血清CEA和CYFRA-21水平同时升高者只有2%。结论:血清CEA≥3.4 ug/L和CYFRA-21≥5.0 ug/L同时升高对肺癌有具有重要的诊断价值,可有效的鉴别原发性肺癌与其它良性病变。     

CYFRA21-1、MMP-3及CEA 和细胞学联合检查对恶性胸腔积液的诊断价值分析

摘要 目的：探讨细胞角蛋白19片段（CYFRA21-1）、基质金属蛋白酶-3（MMP-3）及癌胚抗原（CEA） 和细胞学联合检查对恶性胸腔积液的诊断价值。方法：选择2020年1月至2023年1月我院接诊的100例胸腔积液患者进行研究,并根据病理结果分为实验组47例（病理检查结果恶性）,对照组53例（病理检查结果良性）,分析血清CYFRA21-1、MMP-3及CEA 和细胞学水平变化情况及其的诊断价值。结果：实验组患者血清血清CYFRA21-1、MMP-3及CEA水平显著高于对照组,差异显著（P＜0.05）;实验组患者CYFRA21-1、MMP-3及CEA 和细胞学阳性率均显著高于对照组,差异显著（P＜0.05）;CYFRA21-1诊断恶性胸腔积液的AUC为0.989,95%CI为0.977~1.000;MMP-3诊断恶性胸腔积液的AUC为0.979,95%CI为0.964~0.994;CEA 诊断恶性胸腔积液的AUC为0.982,95%CI为0.967~0.997;细胞学诊断恶性胸腔积液的AUC为0.823,95%CI为0.766~0.879,联合检测时AUC为0.995,95%CI为0.990~1.000,较单独检测曲线下面积比较显著差异;且特异度、准确度均较单独检测更高。结论：CYFRA21-1、MMP-3及CEA 和细胞学联合检查可有效提高诊断恶性胸腔积液的准确性,临床应用价值高。     

P53抗体联合CYFRA21-1和CEA在非小细胞肺癌中的应用

目的：研究血清P53抗体在非小细胞肺癌临床病理特征之间的关系,并结合血清中的癌胚抗原、角质蛋白21-1以指导对临床上肺癌复发和转移的分析,用来选择合理的治疗方案。方法：正常组30例,肺良性疾病组10例,肺癌组45例,肺癌全组分别于手术前1天、术后10、30、60和90天时抽取清晨空腹静脉血2ml,23例肺癌病例于手术后120天,15例病例于手术后180天抽取清晨空腹静脉血2ml,肺良性疾病组分别于手术前1天、抽取清晨空腹静脉血2ml。正常组清晨空腹采集静脉血2ml。采用酶联免疫吸附法（ELISA）检测血清P53抗体和角质蛋白21-1,采用荧光酶标免疫法检测血清癌胚抗原。结果：血清P53抗体、CYFRA21-1和CEA在正常人组、良性疾病组、肺癌组术前阳性率的比较三种肿瘤标志物阳性率经X2检验,在肺癌组分别与正常人组和良性病例组有显著性差异（P〈0.05）,良性病例组和正常人组之间无显著行差异（P〉0.05）。并与手术后复发与转移相关。结论：联合检测癌胚抗原、角质蛋白21-1及血清P53抗体水平有助于肺部良恶性疾病的诊断;手术前后动态测定肺癌患者血清P53抗体和角质蛋白21-1的变化规律,有助于判断疗效,监测预后和指导肺癌术后的综合治疗。     

Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small-cell lung cancer patients

AimTo identify the single-nucleotide polymorphism (SNP) of hENT1 G-706C that is associated with response to gemcitabine-containing chemotherapy, and to determine the prognosis in patients with non-small-cell lung cancer (NSCLC).MethodsPatients with stage III (A + B) or IV NSCLC were recruited for this study (n = 225). Each subject received gemcitabine-containing chemotherapy. The association between human equilibrative nucleoside transporter 1 (hENT1) polymorphism G-706C (rs61758845) and therapeutic effect was evaluated. The SNP hENT1 G-706C was genotyped by polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) assays.ResultsThe polymorphic genotype and the allele frequency of hENT1 G-706C was significantly different between chemotherapy responders and non-responders; to be specific, the response rate of patients carrying an hENT1-706 GG allele was higher than that of patients with a GC or CC genotype. Logistic regression analysis showed that having the GC or CC genotypes was associated with a higher risk of being a non-responder compared with having the GG genotype (OR = 2.34, 95% CI: 1.14–4.80; P = 0.02). The overall survival in patients with the GG genotype was significantly longer than in those with GC or CC genotype (19.0 versus 15.1 months, P < 0.001). The hazard ratio for the (GC + CC) genotype was 1.89 (95% CI: 1.23–2.90) compared with GG carriers (P = 0.004).ConclusionsThe hENT1 genetic polymorphism of hENT1 G-706C was associated with response to the gemcitabine-containing chemotherapy and prognosis of NSCLC. Moreover, assaying this SNP in blood cells may represent a valuable biomarker for individualized treatment for NSCLC patients.     

KCNQ1OT1 facilitates progression of non-small-cell lung carcinoma via modulating miRNA-27b-3p/HSP90AA1 axis

Long noncoding RNA KCNQ1OT1 participates in the regulation of imprinted genes within the kcnq1 domain. But its roles in carcinogenesis and metastasis remain largely elusive. Herein, we evaluated its potential in non-small-cell lung cancer (NSCLC) progression. We demonstrated that the KCNQ1OT1 level was upregulated in NSCLC tissues and cell lines. High KCNQ1OT1 level correlated with poor overall and progression-free survival in NSCLC patients. KCNQ1OT1 facilitated proliferation, migration, and invasion in H460 cells. Furthermore, knockdown of KCNQ1OT1 reduced the expression of HSP90AA1. KCNQ1OT1 presented a positive correlation with HSP90AA1 which predicted the tumor progression in NSCLC from The Cancer Genome Atlas database. Intriguingly, KCNQ1OT1 modulated HSP90AA1 expression by sponging miR-27b-3p. MiR-27b-3p counteracted the effect of KCNQ1OT1 on HSP90AA1 expression, H460 cell migration, and invasion. These data revealed a role for KCNQ1OT1 as an oncogene through miR-27b-3p/HSP90AA1 axis during NSCLC progression.     

多层螺旋CT联合血清糖类抗原19-9、细胞角蛋白19片段抗原、Dickkopf-1蛋白诊断食管癌的临床价值研究

摘要 目的：研究多层螺旋CT（MSCT）联合血清糖类抗原19-9（CA19-9）、细胞角蛋白19片段抗原（CYFRA21-1）、Dickkopf-1蛋白诊断食管癌的临床价值。方法：选择2018年1月～2021年12月江苏省肿瘤医院收治的102例疑似食管癌患者。根据手术病理结果分为恶性组58例以及良性组44例,对所有受试者均进行MSCT扫描,比较两组各项MSCT影像学特征。检测并比较两组血清CA19-9、CYFRA21-1以及Dickkopf-1表达水平。通过Logistic回归建立多指标联合应用的风险预测模型,应用受试者工作特征（ROC）曲线分析MSCT联合血清CA19-9、CYFRA21-1以及Dickkopf-1蛋白诊断食管癌的效能。结果：恶性组MSCT特征表现为形态不规则、边界模糊病例数占比均高于良性组（均P＜0.05）。关联性检验P＜0.05,提示MSCT诊断方法和金标准病理方法显著关联;优势性检验P＞0.05,提示MSCT诊断方法和金标准病理方法优势差异不显著,即MSCT诊断方法是一种较有价值的食管癌诊断方法。恶性组血清CA19-9、CYFRA21-1以及Dickkopf-1表达水平均高于良性组（均P＜0.05）。经ROC曲线分析发现：MSCT联合血清CA19-9、CYFRA21-1以及Dickkopf-1诊断食管癌的曲线下面积（0.863）、灵敏度（0.879）、特异度（0.841）以及约登指数（0.720）均高于MSCT、血清CA19-9、CYFRA21-1以及Dickkopf-1诊断。结论：MSCT联合血清CA19-9、CYFRA21-1以及Dickkopf-1蛋白诊断食管癌的临床价值较高,值得推广应用。     

CircTIMELESS regulates the proliferation and invasion of lung squamous cell carcinoma cells via the miR-136-5p/ROCK1 axis

Numerous studies demonstrate that circular RNAs (circRNAs) are critical regulators of the occurrence and progression of tumors. However, research on the involvement of circRNAs in lung squamous cell carcinoma (LUSC) is limited. In our study, circTIMELESS (also named hsa_circ_0000408 in the Human circRNA Database) was upregulated in both LUSC tissues and LUSC cells, and circTIMELESS expression was positively associated with the TNM stage. Moreover, circTIMELESS silencing markedly suppressed invasion in vitro and disrupted proliferation in vitro as well as in vivo. Additional investigations have shown that circTIMELESS functions as a miR-136-5p “sponge” and regulates miR-136-5p expression. Furthermore, the impact of miR-136-5p upregulation was consistent with the results of circTIMELESS silencing, both of which inhibited the proliferation and invasion of LUSC cells. Additional results showed that Rho-associated coiled-coil containing protein kinase 1 (ROCK1) is targeted by miR-136-5p. The results of recovery experiments showed that ROCK1 overexpression partly rescued the impact of circTIMELESS silencing and miR-136-5p upregulation on proliferation and invasion. Consequently, our findings confirmed that circTIMELESS exists in LUSC and acts as a tumor promoter through the miR-136-5p/ROCK1 axis. Based on these findings, circTIMELESS may be potentially utilized as a therapeutic target for LUSC.     

非小细胞肺癌患者血清CYFRA21-1、VEGF及CEA的表达及与临床病理特征的相关性研究

目的:研究非小细胞肺癌(NSCLC)患者血清细胞角蛋白19片段(CYFRA21-1)、血管内皮生长因子(VEGF)、癌胚抗原(CEA)的表达及与临床病理特征的相关性。方法:选取2015年12月至2016年4月在我院接受治疗的NSCLC患者120例作为观察组,另选取同期在我院接受治疗的肺部良性病变患者50例作为良性对照组,比较两组患者血清中CYFRA21-1、VEGF及CEA的表达,分析观察组患者血清中CYFRA21-1、VEGF及CEA的表达与临床病理特征之间的关系,采用Pearson相关系数分析观察组患者血清中CYFRA21-1、VEGF、CEA的相关性。结果:观察组患者血清中的CYFRA21-1、VEGF及CEA水平均高于良性对照组(P0.05)。鳞状细胞癌患者血清中CYFRA21-1水平高于腺癌患者,CEA水平低于腺癌患者(P0.05),鳞状细胞癌患者和腺癌患者血清中VEGF水平比较无统计学差异(P0.05)。TNM分期为III-IV期的观察组患者血清中CYFRA21-1、VEGF及CEA水平均明显高于I-II期患者,有统计学差异(P0.05)。经Pearson相关系数分析显示,观察组患者血清中CYFRA21-1与VEGF、CEA呈正相关(r=0.512,0.423,P=0.000,0.000),VEGF与CEA呈正相关(r=0.452,P=0.000)。结论:NSCLC患者血清中CYFRA21-1、VEGF及CEA呈高表达,且CYFRA21-1、CEA与病理类型和TNM分期有关,VEGF与TNM分期有关,且三种指标存在一定的相关性。     

顺铂联合立体定向体部放疗治疗晚期肺癌的疗效及对患者血清CYFRA21-1、DR70和肺功能的影响

目的:研究顺铂联合立体定向体部放疗治疗晚期肺癌的疗效及对患者血清角质蛋白21-1(CYFRA21-1)、DR70和肺功能的影响。方法:选择2016年2月到2018年2月在我院诊治的晚期肺癌患者110例,并根据随机数表法将其分为观察组(n=58)和对照组(n=52)。对照组使用常规化疗,观察组采用顺铂联合立体定向体部放疗。比较两组治疗后的疗效、治疗前后血清CYFRA21-1、DR70、第一秒最大呼气量(FEV1)、一秒用力呼气容积/用力肺活量(FEV1/FVC)、最大呼气流速峰值(PEF)及生活质量评分的变化。结果:治疗后,两组患者总有效率分别为86.21%、59.62%,观察组显著高于对照组(P0.05);两组血清CYFRA21-1、DR70水平较治疗前均显著降低(P0.05),且观察组以上指标明显低于对照组(P0.05);两组FEV1、FEV1/FVC、PEF较治疗前均显著升高(P0.05),且观察组以上指标均明显高于对照组(P0.05);两组患者生活质量各项评分均较治疗前明显升高,且观察组患者生活质量各项评分均显著高于对照组(P0.05)。结论:顺铂联合立体定向体部放疗治疗晚期肺癌的临床疗效显著优于单用常规化疗,其可有效改善患者血清CYFRA21-1、DR70水平和肺功能。     

非小细胞肺癌患者外周血循环肿瘤细胞与临床病理特征和血清CEA、NSE、Cyfra21-1、pro-GRP的关系分析

摘要 目的：研究非小细胞肺癌（NSCLC）患者外周血循环肿瘤细胞（CTC）与临床病理特征及血清癌胚抗原（CEA）、神经元特异性烯醇化酶（NSE）、细胞角蛋白21-1（Cyfra21-1）、胃泌素释放肽前体（pro-GRP）的关系。方法：将中山大学附属江门医院从2018年1月～2021年1月收治的100例NSCLC患者纳入研究组,另选取同期我院收治的肺部良性病变患者50例作为对照组。检测并比较两组CTC计数及血清CEA、NSE、Cyfra21-1、pro-GRP水平,分析NSCLC患者外周血CTC与临床病理特征和血清CEA、NSE、Cyfra21-1、pro-GRP水平的关系。此外,通过受试者工作特征（ROC）曲线分析外周血CTC和血清CEA、NSE、Cyfra21-1、pro-GRP诊断NSCLC的效能。结果：研究组外周血CTC计数及血清CEA、NSE、Cyfra21-1、pro-GRP水平均高于对照组,差异有统计学意义（P＜0.05）。Pearson相关性分析结果显示：NSCLC患者外周血CTC计数和血清CEA、NSE、Cyfra21-1、pro-GRP水平均呈正相关（P＜0.05）。TNM分期为Ⅲ～Ⅳ期、有吸烟史的NSCLC患者CTC阳性比例明显高于TNM分期为Ⅰ～Ⅱ期、无吸烟史的NSCLC患者（P＜0.05）。ROC曲线分析结果显示：CTC计数及血清CEA、NSE、Cyfra21-1、pro-GRP水平联合检测诊断NSCLC的曲线下面积最大。结论：NSCLC患者外周血CTC计数升高,与血清CEA、NSE、Cyfra21-1、pro-GRP水平均存在相关性,且CTC阳性与NSCLC恶性进展和患者吸烟史有关,联合检测上述指标诊断NSCLC可获得较为理想的效能。